A specialized drug delivery system using polymeric micelles, which present the apolipoprotein E (ApoE) peptide to target LDLR, was developed to encapsulate sorafenib, a kinase inhibitor that blocks the RAF–MEK–ERK (MAPK) pathway and inhibits cancer cell proliferation. Here, LDLR is linked to cancer.